Evidence map›Paper›PMID 38704518›Full record

ArticleMolecular genetics and genomics : MGG2024

Chromosome-Y haplogroups in Asturias (Northern Spain) and their association with severe COVID-19.

Mar González-Fernández, Daniel Vázquez-Coto, Guillermo M Albaiceta, Laura Amado-Rodríguez, Marta G Clemente, Lucinda Velázquez-Cuervo, Claudia García-Lago, Juan Gómez, Eliecer Coto

Abstract read
In one paragraph

Article in Molecular genetics and genomics : MGG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mar González-Fernández *Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Daniel Vázquez-Coto *Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Guillermo M AlbaicetaInstituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Laura Amado-RodríguezInstituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Marta G ClementeInstituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Lucinda Velázquez-CuervoInstituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Claudia García-LagoInstituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain.
Juan GómezGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Eliecer CotoGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain. cotoeliecer@uniovi.es.ORCID http://orcid.org/0000-0002-8649-9150

Funding

Gobierno del Principado de Asturias FICYT-AYUD/2021/520148Instituto de Salud Carlos III FI-23/00207Instituto de Salud Carlos III ISCIII-PI21/00971Instituto de Salud Carlos III RICOR2040- RD21/0005/0011
6 · The paper itself

Abstract

The main objective of this study was to determine whether the common Y-haplogroups were be associated with the risk of developing severe COVID-19 in Spanish male. We studied 479 patients who required hospitalization due to COVID-19 and 285 population controls from the region of Asturias (northern Spain), They were genotyped for several polymorphisms that define the common European Y-haplogroups. We compared the frequencies between patients and controls aged ≤ 65 and >65 years. There were no different haplogroup frequencies between the two age groups of controls. Haplogroup R1b was less common in patients aged ≤65 years. Haplogroup I was more common in the two patient´s groups compared to controls (p = 0.02). Haplogroup R1b was significantly more frequent among hypertensive patients, without difference between the hypertensive and normotensive controls. This suggested that R1b could increase the risk for severe COVID-19 among male with pre-existing hypertension. In conclusion, we described the Y-haplogroup structure among Asturians. We found an increased risk of severe COVID-19 among haplogroup I carriers, and a significantly higher frequency of R1b among hypertensive patients. These results indicate that Y-chromosome variants could serve as markers to define the risk of developing a severe form of COVID-19.

Indexed as

Chromosomes, Human, YCOVID-19HaplotypesHypertensionSARS-CoV-2AdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPolymorphism, Single NucleotideSpainChromosome-YCOVID-19HaplogroupsHypertension

Identifiers

PMID38704518
PMCPMC11069473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.